Evolocumab

Evolocumab[3] (trade name Repatha) is a monoclonal antibody medication designed for the treatment of hyperlipidemia. Evolocumab is a fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9). PCSK9 is a protein that targets LDL receptors for degradation and its inhibition thereby enhances the liver's ability to remove LDL-C, or "bad" cholesterol, from the blood.[4] Contents 1 Mechanism 2 History 3 Society and culture ... [wikipedia]